Intelligence Feed event · Equity · 2026-09-03

    Fortrea to Acquire Worldwide Clinical Early Phase Unit for $45M

    Question

    Fortrea to Acquire Worldwide Clinical Early Phase Unit for $45M

    Direct answer

    Fortrea entered into a binding agreement to acquire Worldwide Clinical Trials' Early Phase Services unit for roughly $45 million. The deal expands operational footprint across Texas through specialized GLP bioanalytical labs and clinical pharmacology facilities.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-03
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Fortrea to Acquire Worldwide Clinical Early Phase Unit for $45M”, revision 1, evidence through 2026-09-03. https://marketontology.com/market-events/2026-09-03/fortrea-to-acquire-worldwide-clinical-early-phase-unit-for-45m-a833a9

    EQUITY
    Fortrea to Acquire Worldwide Clinical Early Phase Unit for $45M
    Fortrea entered into a binding agreement to acquire Worldwide Clinical Trials' Early Phase Services unit for roughly $45 million. The deal expands operational footprint across Texas through specialized GLP bioanalytical labs and clinical pharmacology facilities.
    FTRE
    Impact
    67
    SEP 3
    SIG
    88%
    FTRE
    Fortrea to Acquire Worldwide Clinical Early Phase Unit for $45M
    Fortrea entered into a binding agreement to acquire Worldwide Clinical Trials' Early Phase Services unit for roughly $45 million. The deal expands operational footprint across Texas through specialized GLP bioanalytical labs and clinical pharmacology facilities.
    → Acquiring clinical pharmacology and bioanalytical assets for $45 million expands FTRE early-stage CRO pipeline capacity and lab service revenue.
    Impact
    Fortrea entered into a binding agreement to acquire Worldwide Clinical Trials' Early Phase Services unit for roughly $45 million. The deal expands operational footprint across Texas through specialized GLP bioanalytical labs and clinical pharmacology facilities.
    Affected
    FTRE
    Transmission
    Acquiring clinical pharmacology and bioanalytical assets for $45 million expands FTRE early-stage CRO pipeline capacity and lab service revenue.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    FTREaccretive laboratory capacity additions to early-phase CRO revenueUp1-3mDefinitive agreement to purchase Early Phase Services division for ~$45M

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month